ArticleDiscover oncology2026
A bibliometric analysis of artificial intelligence in ovarian cancer research from 2006 to 2025.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOvarian cancer is a gynecological malignancy associated with high mortality and poses significant clinical challenges in early diagnosis and precision treatment. Although the rapid advancement of artificial intelligence (AI) has introduced novel approaches to this field, a comprehensive bibliometric overview remains lacking. This study aims to fill this gap by providing a systematic bibliometric analysis of this rapidly evolving domain.
methodsIn this study, the Web of Science Core Collection (WoSCC) was used to retrieve literature on AI applications in ovarian cancer research published from 2006 to the search date (November 19, 2025). Using CiteSpace and VOSviewer, we conducted visual and quantitative analyses of publication trends, countries/regions, institutions, authors, journals, highly cited papers, and keywords.
resultsA total of 786 publications were included in the analysis. The annual publication output showed pronounced exponential growth, with a marked acceleration after 2019. China, the United States, and the United Kingdom were the leading contributing countries. Research hotspots centered on AI-assisted diagnosis, prognostic prediction models, radiomics, and biomarker discovery. The evolution of keywords indicated that frontier research has shifted from basic classification toward more advanced areas, including high-grade serous ovarian carcinoma, multimodal learning, and explainable AI.
conclusionResearch on AI in ovarian cancer has progressed rapidly, with international collaboration concentrated among leading contributors such as China, the USA, and the UK. Future efforts should prioritize the development of explainable and robust clinical AI systems, deeper integration of multimodal data, closer collaboration between clinicians and AI researchers, and high-quality data sharing to facilitate the translation of research findings into precise clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.